Trial Outcomes & Findings for Effect of Acetazolamide on Subclinical High-Altitude Pulmonary Edema Detected by Lung Ultrasonography (NCT NCT03490916)
NCT ID: NCT03490916
Last Updated: 2019-05-10
Results Overview
Edema measured through ultrasound exam
Recruitment status
TERMINATED
Study phase
PHASE4
Target enrollment
18 participants
Primary outcome timeframe
1 month
Results posted on
2019-05-10
Participant Flow
Participant milestones
| Measure |
Acetazolamide Normal Dose
One (1) dose of 250mg of Acetazolamide
Acetazolamide: Administration of Acetazolamide
|
Placebo
One (1) dose of placebo
Placebo: Administration of Placebo
|
|---|---|---|
|
Overall Study
STARTED
|
0
|
0
|
|
Overall Study
COMPLETED
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Effect of Acetazolamide on Subclinical High-Altitude Pulmonary Edema Detected by Lung Ultrasonography
Baseline characteristics by cohort
Baseline data not reported
PRIMARY outcome
Timeframe: 1 monthPopulation: No participants were randomized and no participants received intervention.
Edema measured through ultrasound exam
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: 1 monthPopulation: Participants enrolled but not randomized and did not receive study drug.
Time it takes to complete ultrasound exams
Outcome measures
Outcome data not reported
Adverse Events
Acetazolamide Normal Dose
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Placebo
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place